This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs?
by Ahan Chakraborty
LLY's oncology revenues rise 11% in the first half of 2026, as newer drugs gain traction and pipeline assets add growth opportunities.
LLYPositive Net Change AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
HALOPositive Net Change RGENNegative Net Change IOVANegative Net Change PGENNegative Net Change ARQTNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
by Ahan Chakraborty
Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.
NVOPositive Net Change GPCRPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
by Sundeep Ganoria
BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.
BBIOPositive Net Change ALNYPositive Net Change PFEPositive Net Change
biotechs medical
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
by Sundeep Ganoria
BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.
BBIOPositive Net Change ALNYPositive Net Change PFEPositive Net Change
biotechs medical
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
by Sundeep Ganoria
BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.
BBIOPositive Net Change ALNYPositive Net Change PFEPositive Net Change
biotechs medical
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
by Sundeep Ganoria
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
TEVAPositive Net Change NBIXPositive Net Change RDYPositive Net Change LLYPositive Net Change
biotechs medical
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
by Zacks Equity Research
PFE and BMY both boast strong oncology portfolios, but Pfizer's valuation and broader diversification make it the more attractive pick now.
BMYPositive Net Change PFEPositive Net Change
biotechnology biotechs medical pharmaceuticals
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC
by Zacks Equity Research
Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthening Gilead???s oncology growth opportunity.
GILDPositive Net Change GSKPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?
by Sundeep Ganoria
AbbVie's oncology sales fall 2.4% in Q2 as Imbruvica declines, while Venclexta and newer drugs help offset the pressure.
ABBVPositive Net Change AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals